Interstitial lung abnormalities (ILA), a common finding in low-dose chest CT, are associated with a 5.5-fold increase in risk of lung cancer over long-term follow-up, according to a study reported at the European Respiratory Society (ERS) International Congress 2018.
applications approved by US FDA as of 1 - 15 September 2018 which includes New Molecular Entities (NMEs) and new
biologics. It does not include Tentative Approvals. Supplemental approvals
may have occurred since the original approval date.
Cancer foci detection of quantitative shear wave elastography via the transrectal approach is accurate, a recent study has shown. Additionally, this technique has revealed significant differences between cancerous and benign tissue, indicating its reliability in phenotyping prostate cancer aggressiveness.
The ErbB family blocker afatinib improved progression-free survival (PFS) and overall survival (OS) in treatment-naïve elderly patients with advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm+ NSCLC) compared with platinum doublet chemotherapy or gefitinib, according to subgroup analyses of the LUX-Lung 3*, 6**, and 7*** trials.
Talazoparib, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor, significantly improves progression-free survival (PFS) vs standard chemotherapy in patients with locally advanced or metastatic breast cancer with a germline BRCA1/2 mutation.
The recent “Best of ASCO” event in Singapore saw a battle of wits among leading oncologists in the region during an insightful debate session on the roles of immunotherapy and biomarkers in non-small–cell lung cancer (NSCLC).
According to the Singapore Cancer Registry, ovarian cancer was the fifth most frequent cancer among women in Singapore and accounted for 5.4 percent of all female cancers diagnosed between 2011 and 2015, with an increasing incidence rate through the last four decades.
The combination of irinotecan, fluoropyrimidine (FP), and folinic acid (FA) offered progression-free survival (PFS) and overall survival (OS) benefit as second-line treatment for patients with metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy, according to a meta-analysis.
A novel handheld wireless device proved to be as effective as cardiac magnetic resonance (CMR) imaging in detecting abnormal left ventricular ejection fraction (LVEF) in anthracycline-exposed childhood cancer survivors, a study showed.
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia.